Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study ; volume:14 ; number:1 ; day:31 ; month:5 ; year:2024 ; pages:1-10 ; date:12.2024
Blood cancer journal ; 14, Heft 1 (31.5.2024), 1-10, 12.2024
- Creator
-
Gondran, Camille
Dumas, Pierre-Yves
Bérard, Emilie
Bidet, Audrey
Delabesse, Eric
Tavitian, Suzanne
Leguay, Thibaut
Huguet, Françoise
Borel, Cécile
Forcade, Edouard
Vergez, François
Vial, Jean-Philippe
Rieu, Jean Baptiste
Lechevalier, Nicolas
Luquet, Isabelle
Canali, Alban
Klein, Emilie
Sarry, Audrey
Grande, Anne-Charlotte de
Pigneux, Arnaud
Recher, Christian
Largeaud, Laetitia
Bertoli, Sarah
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-024-01069-9
- URN
-
urn:nbn:de:101:1-2408082125578.792178264781
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gondran, Camille
- Dumas, Pierre-Yves
- Bérard, Emilie
- Bidet, Audrey
- Delabesse, Eric
- Tavitian, Suzanne
- Leguay, Thibaut
- Huguet, Françoise
- Borel, Cécile
- Forcade, Edouard
- Vergez, François
- Vial, Jean-Philippe
- Rieu, Jean Baptiste
- Lechevalier, Nicolas
- Luquet, Isabelle
- Canali, Alban
- Klein, Emilie
- Sarry, Audrey
- Grande, Anne-Charlotte de
- Pigneux, Arnaud
- Recher, Christian
- Largeaud, Laetitia
- Bertoli, Sarah
- SpringerLink (Online service)
Other Objects (12)
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Assessment of BCR-ABL1 Fusion Transcripts and Their Association with Response to Imatinib Treatment in Chronic Myeloid Leukemia Patients
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance
Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
Immunophenotype of myeloid granulocytes in Chinese patients with BCR::ABL1-negative myeloproliferative neoplasms
An unusual case of high hyperdiploid childhood ALL with cryptic BCR/ABL1 rearrangement
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Assessment of BCR-ABL1 Fusion Transcripts and Their Association with Response to Imatinib Treatment in Chronic Myeloid Leukemia Patients
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance
Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
Immunophenotype of myeloid granulocytes in Chinese patients with BCR::ABL1-negative myeloproliferative neoplasms
An unusual case of high hyperdiploid childhood ALL with cryptic BCR/ABL1 rearrangement
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Assessment of BCR-ABL1 Fusion Transcripts and Their Association with Response to Imatinib Treatment in Chronic Myeloid Leukemia Patients
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance
Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
Immunophenotype of myeloid granulocytes in Chinese patients with BCR::ABL1-negative myeloproliferative neoplasms
An unusual case of high hyperdiploid childhood ALL with cryptic BCR/ABL1 rearrangement